UK-headquartered pharmaceutical company GSK has announced plans to spend $1.2bn on manufacturing facilities and digital technology in the US.
The investment includes building a biologics flex factory powered by AI in Upper Merion, Pennsylvania, where it currently has other facilities. Work starts next year on the factory that will manufacture medicines for respiratory disease and cancer.
New AI and digital technologies will be introduced at GSK’s existing five US manufacturing sites, in Maryland, Montana, North Carolina and Pennsylvania.
The company will also build new drug substance manufacturing spaces, auto-injector capabilities and assembly areas.
Emma Walmsley, GSK’s chief executive, said: “Alongside the many longstanding and vital shared interests that connect the UK and the US, is advancing life sciences to get ahead of disease. This week’s state visit brings together two countries that have led the world in science and healthcare innovation.”
The $1.2bn is part of a larger $30bn planned investment across the US over the next five years.
The move comes as other pharmaceutical companies, such as Belgium’s UCB, have planned US factory spends to avoid President Trump’s tariffs on the EU. The changing tariffs have caused uncertainty across the construction sector.
- Subscribe here to get stories about construction around the world in your inbox three times a week
More pharmaceutical news:
